Neurelis, Inc. is an innovation-driven neuroscience company that provides a highly differentiated approach to target unmet medical needs. Neurelis is focused on the development and commercialization of product candidates and innovative delivery technologies for the broader central nervous system (CNS), including epilepsy and psychiatry. We are built on a foundation of people with a passion for progress and a passion for serving the needs of people with neurological disorders and those who care for them. In 2020, Neurelis reached a milestone in patient care with its first FDA-approved treatment. For more information, please visit http://www.neurelis.com.